Medication info

Sevica HCT Tablet 5/40/25 mg

Prescription medicationExpired
Ingredient · strength
Olmesartan Medoxomil›Strength being verifiedAmlodipine Besylate›Strength being verifiedHydrochlorothiazide›Strength being verified
Manufacturer / importer
Daiichi Sankyo Korea Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
Manufacturer packaging unit
Approval status
Expired

MFDS item code 201206779 · Approved 2012.09.13

This product's status changed to Expired on 2023.09.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with amlodipine/olmesartan combination therapy
Who uses it
Adults · Children
Adult dosage
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg ၀ Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ၀ Patients with hepatic impairment Use caution when administering to patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine must not be administered to patients with severe hepatic impairment. ၀ Elderly patients (65 years of age and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. In particular, experience with this medicine in patients 75 years of age and older is very limited, so they should be monitored very carefully when this medicine is administered.
Children's dosage
Under 18 years of age: The safety and efficacy of this medicine have not been established in pediatric patients; therefore, its use is not recommended.

Ingredients

Importer
Daiichi Sankyo Korea Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with amlodipine/olmesartan combination therapy

  • Essential hypertension
View approved original text

This drug helps effectively lower and control blood pressure in patients with essential hypertension who have difficulty controlling blood pressure even with combination therapy using Amlodipine and Olmesartan Medoxomil. By properly managing blood pressure, it is used to reduce the risk of cardiovascular diseases and maintain health.

Dosage and Administration

Adult dosage

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy with amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg ၀ Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine must not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ၀ Patients with hepatic impairment Use caution when administering to patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine must not be administered to patients with severe hepatic impairment. ၀ Elderly patients (65 years of age and older) In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. In particular, experience with this medicine in patients 75 years of age and older is very limited, so they should be monitored very carefully when this medicine is administered.

Children's dosage

Under 18 years of age: The safety and efficacy of this medicine have not been established in pediatric patients; therefore, its use is not recommended.

Precautions

This drug may cause serious harm to the fetus and newborn in the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used by patients who are allergic to this drug or its ingredients, those with certain heart diseases, significantly impaired kidney and liver function, pregnant or breastfeeding women, and patients with specific electrolyte abnormalities. Patients with reduced blood volume or certain kidney diseases should use this drug cautiously as hypotension or deterioration of kidney function may occur, and their condition should be closely monitored. This drug has a blood pressure-lowering effect; therefore, care should be taken when driving or operating machinery as dizziness or symptoms of orthostatic hypotension may occur. This drug may affect potassium levels; therefore, patients at risk of hyperkalemia or hypokalemia should undergo regular blood tests, and caution is needed when combined with potassium supplements or potassium-sparing diuretics. Interactions may occur when used with other medications, so it is essential to consult a specialist, especially when taking with lithium, non-steroidal anti-inflammatory drugs, or other antihypertensives. This drug may cause photosensitivity; thus, it is advisable to pay attention to UV protection during use. Elderly patients or those with impaired kidney or liver function may require dosage adjustments, and they should consult healthcare professionals immediately if any adverse reactions occur. In case of overdose, symptoms such as hypotension and palpitations may appear, so it is crucial to adhere strictly to the prescribed dosage and visit a hospital immediately if any unusual symptoms arise. The safety and efficacy in children or adolescents under 18 years have not been established; therefore, use is not recommended. This drug should be stored in a tightly closed container away from moisture, heat, and direct sunlight, out of the reach of children.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disturbances, neurological abnormalities, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory reduction, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremors, visual disturbances, decreased tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, phototoxic reaction, itching, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, hives, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paraplegia, myalgia, bone pain, frequent urination, acute renal failure, hematuria, urination disorders, nocturia, interstitial nephritis, kidney failure, erectile dysfunction, gynecomastia, weakness, fatigue, chest pain, fever, influenza-like symptoms, lethargy, apathy, edema, pain, facial swelling, increased serum creatinine, increased serum urea, increased serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, increased liver enzymes, increased serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, drug hypersensitivity, upper abdominal pain, decreased libido, chloasma edema, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, acute respiratory distress syndrome (ARDS)

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 to 30 degrees Celsius to preserve the drug's efficacy.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

Manufacturer packaging unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.